论文部分内容阅读
[目的]观察艾迪注射液联合GP方案治疗晚期非小细胞肺癌疗效。[方法]使用随机平行对照方法,将48例住院患者按病志号抽签法简单随机分为两组。对照组24例GP方案:200mg/m2GEM1+100m L生理盐水,30min/次,静滴;250m L生理盐水+5mg地塞米松,快速静滴,d1,d8;25mg/m2DDP+250m L生理盐水,静滴。治疗组24例60m L艾迪注射液+250m L5%葡萄糖注射液,静滴,1次/d;GP方案治疗同对照组。连续治疗21d为1疗程。观测临床症状、瘤体大小、生存质量、KPS评分、不良反应。[结果]KPS生存质量治疗组提高13例,稳定9例,降低2例,总有效率91.67%。对照组提高9例,稳定6例,降低9例,总有效率62.50%。治疗组疗效优于对照组(P<0.05)。体重变化疗效治疗组显效18例,有效2例,无效4例,总有效率83.33%。对照组显效6例,有效7例,无效11例,总有效率54.17%。治疗组疗效优于对照组(P<0.05)。[结论]艾迪注射液联合GP方案治疗晚期非小细胞肺癌效果显著,值得推广。
[Objective] To observe the curative effect of Aidi Injection and GP regimen in the treatment of advanced non-small cell lung cancer. [Methods] Using randomized parallel control method, 48 cases of inpatients were randomly divided into two groups randomly according to the method of lot drawing. Control group, 24 cases of GP regimen: 200mg / m2GEM1 +100 m L normal saline, 30min / times, intravenous infusion; 250m L saline + 5mg dexamethasone, rapid intravenous infusion, d1, d8; Intravenous infusion The treatment group, 24 cases of 60m L Aidi injection + 250m L 5% glucose injection, intravenous infusion, 1 / d; GP regimen with the control group. Continuous treatment of 21d for a course of treatment. Clinical symptoms, tumor size, quality of life, KPS score and adverse reactions were observed. [Result] Thirteen cases were improved in KPS quality of life treatment group, 9 cases were stabilized and 2 cases were reduced. The total effective rate was 91.67%. Control group increased 9 cases, stable in 6 cases, decreased in 9 cases, the total effective rate was 62.50%. The treatment group was better than the control group (P <0.05). Efficacy of weight changes in the treatment group markedly effective in 18 cases, 2 cases, 4 cases, the total effective rate was 83.33%. The control group markedly effective in 6 cases, effective in 7 cases, ineffective in 11 cases, the total effective rate was 54.17%. The treatment group was better than the control group (P <0.05). [Conclusion] Aidi injection combined with GP regimen is effective in treating advanced non-small cell lung cancer and is worth promoting.